Phase 1 7 trials
Phase 1
NCT07574073 Jun 2026 → May 2028 expected autoimmune hemolytic anemia , autoimmune thrombocytopenia Qi deng
Not yet recruiting
No outcome recorded
Phase 1
NCT05684653 Mar → Dec 2023 —
Beijing InnoCare Pharma Tech Co., Ltd.
Unknown
No outcome recorded
Phase 1
NCT05728658 Mar 2023 → Aug 2025 overdue hematopoietic and lymphoid cell neoplasm Beijing InnoCare Pharma Tech Co., Ltd.
Recruiting
No outcome recorded
Phase 1
NCT05660720 Nov 2022 → Jun 2023 —
Beijing InnoCare Pharma Tech Co., Ltd.
Unknown
No outcome recorded
Phase 1
NCT05316857 Dec 2021 → Jan 2022 —
Beijing InnoCare Pharma Tech Co., Ltd.
Completed
No outcome recorded
Phase 1
NCT05036577 Oct 2021 → Dec 2023 overdue primary central nervous system lymphoma Huashan Hospital
Active not recruiting
No outcome recorded
Phase 1
NCT03189017 Jul 2017 → Feb 2018 rheumatoid arthritis , systemic lupus erythematosus Innocare Pharma Australia Pty Ltd
Completed
No outcome recorded
Phase 1/2 8 trials
Phase 1/2
NCT05124028 Dec 2021 → Mar 2022 autoimmune thrombocytopenia Peking University People's Hospital
Unknown
No outcome recorded
Phase 1/2
NCT05021770 Dec 2021 → Dec 2022 non-Hodgkin lymphoma , primary central nervous system lymphoma Huiqiang Huang
Unknown
No outcome recorded
Phase 1/2
NCT04831658 Mar 2021 → Sep 2023 primary central nervous system lymphoma Mingzhi Zhang
Unknown
No outcome recorded
Phase 1/2
NCT04304040 Jul 2020 → Dec 2025 B-cell non-Hodgkin lymphoma Beijing InnoCare Pharma Tech Co., Ltd.
Unknown
No outcome recorded
Phase 1/2
NCT04305197 Jul 2020 → Apr 2022 systemic lupus erythematosus Beijing InnoCare Pharma Tech Co., Ltd.
Completed
No outcome recorded
Phase 1/2
NCT04014205 Nov 2019 → Jun 2026 overdue B-cell neoplasm Beijing InnoCare Pharma Tech Co., Ltd.
Active not recruiting
No outcome recorded
Phase 1/2
NCT03493217 Apr 2018 → Dec 2022 chronic lymphocytic leukemia/small lymphocytic lymphoma Beijing InnoCare Pharma Tech Co., Ltd.
Unknown
No outcome recorded
Phase 1/2
NCT03494179 Apr 2018 → Apr 2020 mantle cell lymphoma Beijing InnoCare Pharma Tech Co., Ltd.
Completed
No outcome recorded
Phase 2 64 trials
Phase 2
NCT07677813 Jun 2026 → Dec 2029 expected MCD diffuse large B-cell lymphoma Ou Bai, MD/PHD
Not yet recruiting
No outcome recorded
Phase 2
NCT07554898 Apr 2026 → Feb 2028 expected MALT lymphoma Zhejiang Cancer Hospital
Recruiting
No outcome recorded
Phase 2
NCT07585747 Apr 2026 → Dec 2029 expected follicular lymphoma Institute of Hematology & Blood Diseases Hospital, China
Not yet recruiting
No outcome recorded
Phase 2
NCT07400250 Apr → Oct 2026 expected autoimmune thrombocytopenia Peking Union Medical College Hospital
Not yet recruiting
No outcome recorded
Phase 2
NCT07453368 Mar 2026 → Mar 2027 expected autoimmune hemolytic anemia Peking Union Medical College Hospital
Recruiting
No outcome recorded
Phase 2
NCT07680933 Mar 2026 → Jun 2027 expected diffuse large B-cell lymphoma The Affiliated Hospital of Xuzhou Medical University
Recruiting
No outcome recorded
Phase 2
NCT07410520 Feb 2026 → Dec 2028 expected central nervous system non-hodgkin lymphoma The First Affiliated Hospital with Nanjing Medical University
Recruiting
No outcome recorded
Phase 2
NCT07441993 Jan 2026 → Dec 2027 expected marginal zone lymphoma Institute of Hematology & Blood Diseases Hospital, China
Recruiting
No outcome recorded
Phase 2
NCT07499271 Jan 2026 → Dec 2027 expected diffuse large B-cell lymphoma The First Affiliated Hospital of Soochow University
Recruiting
No outcome recorded
Phase 2
NCT07372365 Oct 2025 → Apr 2028 expected marginal zone lymphoma The First Affiliated Hospital of Soochow University
Recruiting
No outcome recorded
Phase 2
NCT07480863 Oct 2025 → Oct 2029 expected marginal zone lymphoma Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Active not recruiting
No outcome recorded
Phase 2
NCT07206264 Oct 2025 → Dec 2027 expected mantle cell lymphoma Tianjin Medical University Cancer Institute and Hospital
Not yet recruiting
No outcome recorded
Phase 2
NCT07247383 Sep 2025 → Dec 2027 expected marginal zone lymphoma , ocular adnexal lymphoma Second Affiliated Hospital, School of Medicine, Zhejiang University
Active not recruiting
No outcome recorded
Phase 2
NCT07272499 Sep 2025 → Sep 2028 expected mantle cell lymphoma Ruijin Hospital
Recruiting
No outcome recorded
Phase 2
NCT07208981 Aug 2025 → Jun 2028 expected marginal zone lymphoma The First Affiliated Hospital with Nanjing Medical University
Recruiting
No outcome recorded
Phase 2
NCT07199296 Jul 2025 → Jul 2028 expected mantle cell lymphoma Ruijin Hospital
Recruiting
No outcome recorded
Phase 2
NCT07008053 Jul 2025 → Jul 2027 expected marginal zone lymphoma Tianjin Medical University Cancer Institute and Hospital
Not yet recruiting
No outcome recorded
Phase 2
NCT07078500 May 2025 → Oct 2026 expected diffuse large B-cell lymphoma Second Affiliated Hospital, School of Medicine, Zhejiang University
Recruiting
No outcome recorded
Phase 2
NCT07448324 Apr 2025 → Jan 2028 expected marginal zone lymphoma The First Affiliated Hospital with Nanjing Medical University
Recruiting
No outcome recorded
Phase 2
NCT06901999 Apr 2025 → Nov 2026 expected central nervous system non-hodgkin lymphoma Ruijin Hospital
Not yet recruiting
No outcome recorded
Phase 2
NCT07022223 Mar 2025 → Sep 2027 expected marginal zone lymphoma Second Affiliated Hospital, School of Medicine, Zhejiang University
Recruiting
No outcome recorded
Phase 2
NCT06793189 Jan 2025 → Dec 2028 expected marginal zone lymphoma Ruijin Hospital
Recruiting
No outcome recorded
Phase 2
NCT06701357 Dec 2024 → Dec 2026 expected diffuse large B-cell lymphoma Ruijin Hospital
Recruiting
No outcome recorded
Phase 2
NCT06700798 Dec 2024 → May 2026 overdue marginal zone lymphoma Fei Li
Recruiting
No outcome recorded
Phase 2
NCT06656221 Dec 2024 → Dec 2026 expected mantle cell lymphoma Ruijin Hospital
Not yet recruiting
No outcome recorded
Phase 2
NCT06985472 Nov 2024 → Dec 2025 overdue marginal zone lymphoma Li Zhiming
Recruiting
No outcome recorded
Phase 2
NCT06647940 Nov 2024 → Nov 2026 expected diffuse large B-cell lymphoma Sun Yat-sen University
Recruiting
No outcome recorded
Phase 2
NCT06516978 Oct 2024 → Oct 2028 expected diffuse large B-cell lymphoma The First Affiliated Hospital with Nanjing Medical University
Not yet recruiting
No outcome recorded
Phase 2
NCT06583837 Sep 2024 → Aug 2025 overdue marginal zone lymphoma Fudan University
Active not recruiting
No outcome recorded
Phase 2
NCT06566807 Aug 2024 → Aug 2026 overdue marginal zone lymphoma Huai'an First People's Hospital
Recruiting
No outcome recorded
Phase 2
NCT06530511 Aug 2024 → Feb 2026 overdue diffuse large B-cell lymphoma Affiliated Hospital of Nantong University
Recruiting
No outcome recorded
Phase 2
NCT06476899 Jul 2024 → Mar 2026 overdue chronic lymphocytic leukemia/small lymphocytic lymphoma Fei Li
Not yet recruiting
No outcome recorded
Phase 2
NCT06513234 Jul 2024 → Jun 2026 overdue marginal zone lymphoma Institute of Hematology & Blood Diseases Hospital, China
Recruiting
No outcome recorded
Phase 2
NCT06504940 Jun 2024 → Jul 2027 expected marginal zone lymphoma First Affiliated Hospital of Zhejiang University
Recruiting
No outcome recorded
Phase 2
NCT06454968 Jun 2024 → Jun 2026 overdue marginal zone lymphoma Peking Union Medical College Hospital
Recruiting
No outcome recorded
Phase 2
NCT06228963 Mar 2024 → Jan 2026 overdue Helicobacter pylori infectious disease , gastric mucosa-associated lymphoid tissue lymphoma Fudan University
Recruiting
No outcome recorded
Phase 2
NCT06503276 Nov 2023 → Oct 2025 overdue marginal zone lymphoma Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Recruiting
No outcome recorded
Phase 2
NCT05978739 Aug 2023 → Dec 2024 mantle cell lymphoma InnoCare Pharma Inc.
Completed
No outcome recorded
Phase 2
NCT05926427 Aug 2023 → Apr 2026 central nervous system non-hodgkin lymphoma Ruijin Hospital
Unknown
No outcome recorded
Phase 2
NCT05918276 Jul 2023 → Dec 2024 overdue chronic lymphocytic leukemia/small lymphocytic lymphoma Nanfang Hospital, Southern Medical University
Not yet recruiting
No outcome recorded
Phase 2
NCT05933967 Jun 2023 → Dec 2024 overdue —
Shandong Cancer Hospital and Institute
Recruiting
No outcome recorded
Phase 2
NCT05688696 Apr 2023 → Aug 2025 overdue systemic lupus erythematosus Beijing InnoCare Pharma Tech Co., Ltd.
Recruiting
No outcome recorded
Phase 2
NCT06290817 Mar 2023 → Mar 2025 diffuse large B-cell lymphoma Second Affiliated Hospital, School of Medicine, Zhejiang University
Unknown
No outcome recorded
Phase 2
NCT05600660 Aug 2022 → Dec 2025 overdue primary central nervous system lymphoma Second Affiliated Hospital, School of Medicine, Zhejiang University
Recruiting
No outcome recorded
Phase 2
NCT05498259 Jul 2022 → Jan 2024 diffuse large B-cell lymphoma The First Affiliated Hospital of Soochow University
Unknown
No outcome recorded
Phase 2
NCT05381506 Jul 2022 → Dec 2023 diffuse large B-cell lymphoma Sun Yat-sen University
Unknown
No outcome recorded
Phase 2
NCT05549284 Jun 2022 → May 2023 primary central nervous system lymphoma Affiliated Hospital to Academy of Military Medical Sciences
Unknown
No outcome recorded
Phase 2
NCT05322733 Apr 2022 → Feb 2025 chronic lymphocytic leukemia/small lymphocytic lymphoma The First Affiliated Hospital with Nanjing Medical University
Unknown
No outcome recorded
Phase 2
NCT05390749 Apr 2022 → Apr 2024 primary central nervous system lymphoma Peking Union Medical College Hospital
Unknown
No outcome recorded
Phase 2
NCT05232149 Feb 2022 → Dec 2023 autoimmune thrombocytopenia Beijing InnoCare Pharma Tech Co., Ltd.
Unknown
No outcome recorded
Phase 2
NCT05491044 Jan 2022 → Aug 2024 chronic lymphocytic leukemia/small lymphocytic lymphoma Peking University People's Hospital
Unknown
No outcome recorded
Phase 2
NCT06454266 Dec 2021 → Jun 2024 primary central nervous system lymphoma Ningbo No. 1 Hospital
Completed
No outcome recorded
Phase 2
NCT05209620 Dec 2021 → Jun 2025 overdue central nervous system cancer Henan Cancer Hospital
Recruiting
No outcome recorded
Phase 2
NCT05076097 Sep 2021 → Oct 2022 mantle cell lymphoma Tianjin Medical University Cancer Institute and Hospital
Unknown
No outcome recorded
Phase 2
NCT05014100 Sep 2021 → Sep 2022 lymphoma Puyang Oilfield General Hospital
Unknown
No outcome recorded
Phase 2
NCT05020288 Sep 2021 → Dec 2023 autoimmune thrombocytopenia Shandong University
Unknown
No outcome recorded
Phase 2
NCT04989621 Aug 2021 → Aug 2026 overdue follicular lymphoma Sun Yat-sen University
Recruiting
No outcome recorded
Phase 2
NCT04961515 Jul 2021 → Dec 2025 overdue primary central nervous system lymphoma Second Affiliated Hospital, School of Medicine, Zhejiang University
Recruiting
No outcome recorded
Phase 2
NCT04899427 Mar 2021 → Mar 2023 primary central nervous system lymphoma Peking Union Medical College Hospital
Unknown
No outcome recorded
Phase 2
NCT04711148 Mar 2021 → Feb 2026 relapsing-remitting multiple sclerosis Beijing InnoCare Pharma Tech Co., Ltd.
Unknown
No outcome recorded
Phase 2
NCT04438005 May 2020 → Nov 2021 diffuse large B-cell lymphoma Beijing InnoCare Pharma Tech Co., Ltd.
Completed
No outcome recorded
Phase 2
NCT04440059 Aug 2019 → Jan 2024 Waldenstrom macroglobulinemia Beijing InnoCare Pharma Tech Co., Ltd.
Completed
No outcome recorded
Phase 2
NCT04438044 Jun 2019 → Dec 2023 central nervous system non-hodgkin lymphoma Beijing InnoCare Pharma Tech Co., Ltd.
Unknown
No outcome recorded
Phase 2
NCT03797456 Apr 2019 → Dec 2023 marginal zone lymphoma Beijing InnoCare Pharma Tech Co., Ltd.
Completed
No outcome recorded
Show 54 more trials Phase 2/3 1 trial
Phase 2/3
NCT07185373 Oct 2025 → Sep 2028 expected primary central nervous system lymphoma Huashan Hospital
Not yet recruiting
No outcome recorded
Phase 3 13 trials
Phase 3
NCT07559331 Apr 2026 → Apr 2027 expected primary thrombocytopenia Shandong University
Recruiting
No outcome recorded
Phase 3
NCT07299019 Mar 2026 → Jun 2030 expected secondary progressive multiple sclerosis Zenas BioPharma (USA), LLC
Recruiting
No outcome recorded
Phase 3
NCT07067463 Mar 2026 → Jun 2030 expected primary progressive multiple sclerosis Zenas BioPharma (USA), LLC
Recruiting
No outcome recorded
Phase 3
NCT06496308 Jul 2024 → Jul 2027 expected mantle cell lymphoma Ruijin Hospital
Recruiting
No outcome recorded
Phase 3
NCT06082102 Dec 2023 → Aug 2028 expected marginal zone lymphoma Beijing InnoCare Pharma Tech Co., Ltd.
Recruiting
No outcome recorded
Phase 3
NCT06004856 Oct 2023 → Dec 2025 autoimmune thrombocytopenia Beijing InnoCare Pharma Tech Co., Ltd.
Unknown
No outcome recorded
Phase 3
NCT05234684 Nov 2022 → Jul 2024 diffuse large B-cell lymphoma Beijing InnoCare Pharma Tech Co., Ltd.
Unknown
No outcome recorded
Phase 3
NCT05351346 Jun 2022 → Jun 2026 diffuse large B-cell lymphoma Ruijin Hospital
Unknown
No outcome recorded
Phase 3
NCT05051891 Dec 2021 → Jun 2025 mantle cell lymphoma Beijing InnoCare Pharma Tech Co., Ltd.
Completed
No outcome recorded
Phase 3
NCT05334238 Dec 2021 → May 2024 primary central nervous system lymphoma Ruijin Hospital
Unknown
No outcome recorded
Phase 3
NCT05020392 Sep 2021 → Oct 2023 B-cell chronic lymphocytic leukemia , Burkitt lymphoma , diffuse large B-cell lymphoma , follicular lymphoma +1 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Unknown
No outcome recorded
Phase 3
NCT05097443 Apr 2021 → Dec 2023 high grade B-cell lymphoma , high grade B-cell lymphoma with MYC and/ or BCL2 and/or BCL6 rearrangement , mantle cell lymphoma Shandong Provincial Hospital
Unknown
No outcome recorded
Phase 3
NCT04578613 Jan 2021 → Dec 2024 chronic lymphocytic leukemia/small lymphocytic lymphoma Beijing InnoCare Pharma Tech Co., Ltd.
Unknown
No outcome recorded
Show 3 more trials Phase 4 1 trial
Phase 4
NCT07355699 Nov 2025 → Sep 2027 expected marginal zone lymphoma Beijing Tongren Hospital
Recruiting
No outcome recorded
Phase not applicable 8 trials
— NCT07191431 Sep 2025 → Sep 2027 expected central nervous system non-hodgkin lymphoma Ruijin Hospital
Recruiting
No outcome recorded
— NCT07257510 Aug 2025 → Aug 2028 expected mantle cell lymphoma Peking University Third Hospital
Recruiting
No outcome recorded
— NCT07072208 Nov 2024 → May 2027 expected diffuse large B-cell lymphoma The First Affiliated Hospital of Soochow University
Recruiting
No outcome recorded
— NCT06478472 Jun 2024 → Jun 2027 expected marginal zone lymphoma The First Affiliated Hospital of Xiamen University
Recruiting
No outcome recorded
— NCT05784987 Apr 2023 → Jan 2024 diffuse large B-cell lymphoma The First Affiliated Hospital with Nanjing Medical University
Unknown
No outcome recorded
— NCT05809180 Jan 2023 → Jul 2025 diffuse large B-cell lymphoma The First Affiliated Hospital of Soochow University
Unknown
No outcome recorded
— NCT05284175 Apr 2022 → Aug 2023 neuromyelitis optica spectrum disorder with anti-AQP4 antibodies Peking Union Medical College Hospital
Unknown
No outcome recorded
— NCT04441450 Jul → Aug 2019 —
Beijing InnoCare Pharma Tech Co., Ltd.
Completed
No outcome recorded